Sundance Strategies, Inc. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ___________ to ___________ Commission File Number 000-50547 SUNDANCE STRATEGIES, INC. (Exact name of registrant as specified in its charter) Nevada 88-0515333 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4626 North 300 West , Suite No. 365 , Provo , Utah 84604 (Address of principal executive offices) (Zip Code) (801) 717-3935 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: None Securities registered pursuant to Section 12(g) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SUND OTCQB Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company. See the definitions of “ large accelerated filer ,” “ accelerated filer ” “ smaller reporting company ” and “ emerging growth company ” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging Growth Company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒ As of November 14, 2022, the registrant had 41,408,441 shares of common stock, par value $0.001, issued and outstanding. SUNDANCE STRATEGIES, INC. FORM 10-Q TABLE OF CONTENTS Page PART I — FINANCIAL INFORMATION 3 Item 1. Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and March 31, 2022 3 Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2022 and 2021 (Unaudited) 4 Condensed Consolidated Statements of Stockholders’ Deficit for the three and six months ended September 30, 2022 and 2021 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2022 and 2021 (Unaudited) 6 Notes to Condensed Consolidated Financial Statements September 30, 2022 (Unaudited) 7 Item 2. Management’s Discussion and Analysis of Financial Condition And Results of Operations 13 Item 3. Quantitative and Qualitative Disclosure about Market Risk 17 Item 4. Controls and Procedures 17 PART II — OTHER INFORMATION 18 Item 1. Legal Proceedings 18 Item 1A. Risk Factors 18 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 18 Item 3. Defaults upon Senior Securities 18 Item 4. Mine Safety Disclosures 18 Item 5. Other Information 18 Item 6. Exhibits 19 Signatures 20 2 PART I — FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) SUNDANCE STRATEGIES, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets 2022 2022 September 30, 2022 March 31, (Unaudited) 2022 ASSETS Current Assets Cash and cash equivalents $ 498 $ 267,966 Prepaid expenses and other assets 1,167 8,167 Total Current Assets $ 1,665 $ 276,133 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current Liabilities Accounts payable $ 665,270 $ 580,972 Accrued expenses 455,039 354,205 Notes payable 300,000 300,000 Current portion of notes payable, related parties 876,000 876,000 Stock repurchase payable 400,000 400,000 Total Current Liabilities 2,696,309 2,511,177 Long-Term Liabilities Accrued expenses 758,952 666,015 Notes payable, related parties, net of current portion 2,125,808 2,125,808 - - Total Long-Term Liabilities 2,884,760 2,791,823 Total Liabilities 5,581,069 5,303,000 Stockholders’ Deficit Preferred stock, authorized 10,000,000 shares, par value $ 0.001 ; - 0 - shares issued and outstanding - - Common stock, authorized 500,000,000 shares, par value $ 0.001 ; 41,408,441 shares issued and outstanding as of September 30, and March 31, 2022 41,409 41,409 Additional paid-in capital 27,181,618 27,181,618 Accumulated deficit ( 32,802,431 ) ( 32,249,894 ) Total Stockholders’ Deficit ( 5,579,404 ) ( 5,026,867 ) Total Liabilities and Stockholders’ Deficit $ 1,665 $ 276,133 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY Condensed Consolidated Statements of Operations (Unaudited) 2022 2021 2022 2021 Three Months Ended September 30, Six Months Ended September 30, 2022 2021 2022 2021 Income from Investments $ - $ - $ - $ - General and Administrative Expenses 161,534 172,144 375,491 415,605 Loss from Operations ( 161,534 ) ( 172,144 ) ( 375,491 ) ( 415,605 ) Other Income (Expense) Gain on settlement of liabilities - - - 285,192 Interest expense ( 75,907 ) ( 68,352 ) ( 150,046 ) ( 133,737 ) Financing expense ( 13,500 ) ( 10,000 ) ( 27,000 ) ( 87,561 ) Total Other Income (Expense) ( 89,407 ) ( 78,352 ) ( 177,046 ) 63,894 Loss Before Income Taxes ( 250,941 ) ( 250,496 ) ( 552,537 ) ( 351,711 ) Income Tax Provision (Benefit) - 4,149 - 4,149 Net Loss $ ( 250,941 ) $ ( 254,645 ) $ ( 552,537 ) $ ( 355,860 ) Loss per share - basic and diluted $ ( 0.01 ) $ ( 0.01 ) $ ( 0.01 ) $ ( 0.01 ) Weighted average shares outstanding - basic and diluted 41,408,441 41,308,441 41,408,441 41,086,702 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY Condensed Consolidated Statements of Stockholders’ Deficit For the Six Months Ended September 30, 2022 and 2021 (Unaudited) Shares Amount Capital Deficit Deficit Common Stock Additional Paid-In Accumulated Total Stockholders’ Shares Amount Capital Deficit Deficit Balance, March 31, 2022 41,408,441 $ 41,409 $ 27,181,618 $ ( 32,249,894 ) $ ( 5,026,867 ) Net loss - - - ( 301,596 ) ( 301,596 ) Balance, June 30, 2022 41,408,441 41,409 27,181,618 ( 32,551,490 ) ( 5,328,463 ) Net loss - - - ( 250,941 ) ( 250,941 ) Balance, September 30, 2022 41,408,441 41,409 27,181,618 ( 32,802,431 ) ( 5,579,404 ) Balance, March 31, 2021 40,108,441 40,109 24,728,638 ( 29,484,809 ) ( 4,716,062 ) Common stock issued for director compensation 1,200,000 1,200 54,240 - 55,440 Net loss - - - ( 101,215 ) ( 101,215 ) Balance, June 30, 2021 41,308,441 $ 41,309 $ 24,782,878 $ ( 29,586,024 ) $ ( 4,761,837 ) Stock-based compensation - director shares - - 18,480 - 18,480 Net loss - - - ( 254,645 ) ( 254,645 ) Balance, September 30, 2021 41,308,441 41,309 24,801,358 ( 29,840,669 ) ( 4,998,002 ) The accompanying notes are an integral part of these condensed consolidated financial statements. 5 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY Condensed Consolidated Statements of Cash Flows (Unaudited) 2022 2021 Six Months Ended September 30, 2022 2021 Operating Activities Net Loss $ ( 552,537 ) $ ( 355,860 ) Adjustments to reconcile to net cash used in operating activities: Share based compensation - common stock - 73,920 Gain on settlement of liabilities - ( 285,192 ) Changes in operating assets and liabilities Prepaid expenses and other assets 7,000 ( 8,250 ) Accounts payable 84,298 ( 57,267 ) Accrued expenses 193,771 152,409 Net Cash used in Operating Activities ( 267,468 ) ( 480,240 ) Financing Activities Proceeds from issuance of notes payable, related party - 160,000 Proceeds from issuance of notes payable - 300,000 Net Cash provided by Financing Activities - 460,000 Net Change in Cash and Cash Equivalents ( 267,468 ) ( 20,240 ) Cash and Cash Equivalents at Beginning of Period 267,966 21,179 Cash and Cash Equivalents at End of Period $ 498 $ 939 Supplemental disclosure of cash flow information: Cash paid for interest $ - $ - Cash paid for income taxes $ - $ - The accompanying notes are an integral part of these Condensed Consolidated financial statements. No Assurance is provided on these financial statements 6 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) September 30, 2022 (1) BASIS OF PRESENTATION, ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting and reflect the financial position, results of operations and cash flows of the Company. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, these unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2022, which was filed with the SEC on June 29, 2022. The results from operations for the three and six-month periods ended September 30, 2022, are not necessarily indicative of the results that may be expected for the fiscal year ended March 31, 2023. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, stockholders’ equity, and cash flows at June 30, 2022 and for all periods presented herein have been made. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in the Company’s financial statements and the accompanying notes. Actual results could materially differ from those estimates. Organization and Nature of Operations Sundance Strategies, Inc. (formerly known as Java Express, Inc.) was organized under the laws of the State of Nevada on December 14, 2001, and engaged in the retail selling of beverage products to the general public until these endeavors ceased in 2006; it had no material business operations from 2006, until its acquisition of ANEW LIFE, INC. (“ANEW LIFE”), a subsidiary of Sundance Strategies, Inc. (“Sundance Strategies”, “the Company”, “we” or “our”). Our historical business model has focused on purchasing or acquiring life insurance policies and residual interests in or financial products tied to life insurance policies, including notes, drafts, acceptances, open accounts receivable and other obligations representing part of or all of the sales price of insurance, life settlements and related insurance contracts being traded in the secondary marketplace, often referred to as the “life settlements market.” During the latter part of the fiscal year ended March 31, 2021, the Company began developing an additional business offering, providing professional services to specialty structured finance groups, bond issuers and life settlement aggregators. The Company has now assembled an experienced team from the life settlement marketplace, as well as from other areas such as financial services and public financial markets. As a professional services provider, the Company applies industry best practices to advise on the selection of specific portfolios of life insurance policies that are tailored to meet the needs of its clients. The Company’s clients may include bond issuers, bond investors, or other structured finance product issuers. The Company develops strategies and methodologies which include the acquisition of life insurance portfolios, then uses common structured finance techniques and proprietary analytics to structure bonds for issuances, including principal protected bonds. The Company’s goal is to deliver long-term value and profitability to shareholders by growing the Company’s professional services business and asset base, resulting in the ability to pay dividends to its shareholders. During the latter part of the year ended March 31, 2021, we began working closely with bond placement agents and aggregators to establish various aspects of a proprietary, investment grade bond offering. In this arrangement, we participate as the sole originator in the role of structuring and advising on the structure of the proprietary bond instrument. Included in the role of structuring financial assets, we use proprietary analytics to establish the makeup of the rated instrument, including but not limited to, life settlement assets (life insurance policies) and managed cash, and implements a process of selective assembly of the underlying assets and cash management that will meet the policy requirements and analytics. We provide current and ongoing resources for all analytics, as well as advisement support for the investment and non-investment grade ratings for the managed asset pool and the managed cash accounts. In our advisory role, we are reimbursed for all expenses associated with the structuring and preparation of any bond offering, will receive an advisory payment upon the closing of any bond offering, and then will hold residual rights on the balance of assets once the bond is retired. 7 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) September 30, 2022 On January 1, 2022, we entered into a marketing and consulting agreement with Tradability, LLC (“Consultant”) that requires us to make an initial $ 100,000 payment and up to an additional $ 400,000 in the future (which will be financed by the Consultant via a promissory note). The $ 400,000 obligation is contingent upon the Consultant and us successfully reaching certain milestones. Further, the agreement requires us to issue between 1,000,000 and 10,000,000 stock options (which are exercisable into our common stock at prices between $ 1.00 to $ 2.50 per share) contingent upon the Consultant and us successfully reaching certain milestones. The milestones primarily relate to the Consultant finalizing the tokenization of 500 million non-fungible tokens (“NFTs”) and the successful placement of NFTs with proceeds of between $ 100 million and $ 500 million. The proceeds will be used to purchase Life Settlements for which we will be an advisor. As of September 30, 2022 none of the milestones related to the potential issuance of equity have been met. Significant Accounting Policies There have been no changes to the significant accounting policies of the Company from the information provided in Note 2 of the Notes to Consolidated Financial Statements in the Company’s most recent Form 10-K, except as discussed below. Basic and Diluted Net Income (Loss) Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the periods presented using the treasury stock method. Diluted net loss per common share is computed by including common shares that may be issued subject to existing rights with dilutive potential, when applicable. Potential dilutive common stock equivalents are primarily comprised of potential dilutive shares resulting from convertible debt agreements and common stock warrants. Potentially dilutive shares resulting from convertible debt agreements are evaluated using the if-converted method. Potentially dilutive securities are not included in the calculation of diluted net loss per share for the three and six months ended September 30, 2022 and 2021, because to do so would be anti-dilutive. Potentially dilutive securities outstanding as of September 30, 2022 and 2021 are comprised of warrants convertible into 7,250,241 and 4,758,754 shares of common stock, respectively. New Accounting Pronouncements Adopted During the Six Months Ended September 30, 2022 In May 2021, the FASB issued ASU 2021-04 Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity Classified Written Call Options. This ASU clarifies an issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. Specifically, it provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. The amendment is effective for fiscal years beginning after December 15, 2021, and interim periods therein. The Company adopted the new guidance as of April 1, 2022, and used the framework to record modification to the exercise price of equity classified warrants during the six months ended September 30, 2022. Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements. 8 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) September 30, 2022 (2) LIQUIDITY REQUIREMENTS Since the Company’s inception on January 31, 2013, its operations have been primarily financed through sales of equity, debt financing from related parties and the issuance of notes payable and convertible debentures. As of September 30, 2022, the Company had $ 498 of cash assets, compared to $ 267,966 as of March 31, 2022. As of September 30, 2022, the Company had access to draw an additional $ 4,604,192 on the notes payable, related party (see Note 6) and $ 3,000,000 on the Convertible Debenture Agreement (See Note 7). For the six months ended September 30, 2022, the Company’s average monthly operating expenses were approximately $ 62,500 , which includes salaries of our employees, consulting agreements and contract labor, general and administrative expenses and legal and accounting expenses. In addition to the monthly operating expenses, the Company continues to pursue other debt and equity financing opportunities, and as a result, financing expenses of $ 13,500 were incurred during the three months ended September 30, 2022. As management continues to explore additional financing alternatives, beginning October 1, 2022 the Company is expected to spend up to an additional $ 400,000 on these efforts. Outstanding Accounts Payable as of September 30, 2022 totaled $ 665,270 . Management has concluded that its existing capital resources and availability under its existing convertible debentures and debt agreements with related parties will be sufficient to fund its operating working capital requirements for at least the next 12 months, or through November 2023. Related parties have given assurance that their continued support, by way of either extensions of due dates, or increases in lines-of-credit, can be relied on. As mentioned above, the Company also continues to evaluate other debt and equity financing opportunities. The outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely. The accompanying financial statements have been prepared on a going concern basis under which the Company is expected to be able to realize its assets and satisfy its liabilities in the normal course of business. (3) FAIR VALUE MEASUREMENTS As defined by ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also requires the consideration of differing levels of inputs in the determination of fair values. Those levels of input are summarized as follows: ● Level 1: Quoted prices in active markets for identical assets and liabilities. ● Level 2: Observable inputs other than Level 1 quoted prices, such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. ● Level 3: Unobservable inputs that are supported by little or no market activity. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques as well as instruments for which the determination of fair value requires significant management judgment or estimation. 9 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) September 30, 2022 The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company did not have any transfers of assets and liabilities between Levels 1, 2 and 3 of the fair value measurement hierarchy during the six months ended September 30, 2022 and 2021. Other Financial Instruments The Company’s recorded values of cash and cash equivalents, prepaid expenses and other assets, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded values of the notes payable and convertible debenture approximate the fair values as the interest rate approximates market interest rates. (4) STOCKHOLDERS’ EQUITY Common Stock Effective December 6, 2018, three existing stockholders have contributed to the Company a portion of their common shares held at a repurchase price to the Company of $ 0.05 per share. The Company has cancelled the acquired shares, which decreased the outstanding common shares on the books of the Company. The total number of common shares canceled/retired was 8,000,000 . 6,000,000 of the 8,000,000 shares were owned by a related party to the Company. The total liability related to the repurchase of these shares is $ 400,000 , with repayment to the related party stockholders contingent on a major financing event. $ 300,000 of the $ 400,000 liability is to a related party. Warrants to Purchase Common Stock The Company’s related party lenders consist of: the Chairman of the Board of Directors and a stockholder, Radiant Life, LLC and Mr. Dickman, a board member and stockholder. These holders of the related party unsecured promissory notes, hold agreements that provide each related party with common stock warrants upon the lender’s extension of a maturity due date or upon the loaning of additional monies. The number of warrants issued for an extension is based on the following formula: 10,000 warrants per month the due date is extended plus 1 warrant for every $2 of the principal balance outstanding (not including interest) at the time of the extension (rounded to the nearest whole warrant). Upon the loaning of additional monies, the lender will also require 2 warrants for each dollar loaned. All warrants issued under these terms vested immediately upon issuance, have an exercise price approximately equal to the fair value of the Company’s common stock on the date of grant, and expire 5 years from the date of issuance. On June 20, 2022, the Company amended the agreements with the related party lenders to adjust the exercise price of the warrants issued in conjunction with extensions of due dates and new monies lent on the outstanding notes payable, related parties from January 5, 2022 to February 5, 2022 . The original agreements stated that the exercise price of the warrants issued was $ 0.05 . The amended agreements adjust the exercise price from $ 0.05 to $ 1.05 , which is the estimated fair market value of the common stock on the grant dates of the warrants. The original agreements inadvertently stated an exercise price of $ 0.05 , when the Company had intended to grant warrants with an exercise price of $ 1.05 . This modification was evaluated and it was determined that the increase in exercise price resulted in a decrease in the fair value of the warrants issued from January 5, 2022 to February 5, 2022, and therefore no additional warrant expense was required. 10 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) September 30, 2022 The following table summarizes the warrants issued and outstanding as of September 30, 2022: SCHEDULE OF WARRANTS ISSUED AND OUTSTANDING Exercise Price ($) Warrants Outstanding Warrants Exercisable Weighted Average Remaining Contractual Life (Years) Proceeds to Company if Exercised 0.05 3,708,754 3,708,754 2.70 $ 185,439 1.00 1,000,000 1,000,000 1.52 1,000,000 1.05 2,534,487 2,534,487 4.51 2,661,211 2.00 50,000 50,000 3.85 100,000 5.00 500,000 500,000 4.32 2,500,000 7,793,241 7,793,241 $ 6,446,650 The shares of common stock issuable upon exercise of the warrants are not registered with the Securities and Exchange Commission and the holders of the warrants do not have registration rights with respect to the warrants or the underlying shares of common stock. (5) NOTES PAYABLE On April 6, 2021, the Company borrowed $ 300,000 under an unsecured promissory note with Satco International, Ltd. This promissory note bears interest at a rate of 8 % annually and was due September 6, 2022 . In conjunction with this note, the Company issued warrants for 1,000,000 shares of common stock, exercisable at $ 1.00 per share and expiring in 3 years from the date of the promissory note. On October 19, 2022, the unsecured promissory note with Satco International, Ltd. was amended to extend the due date from September 6, 2022 to January 6, 2023 , or at the immediate time when alternative financing or other proceeds are received. This extension has no bearing on the warrants that were issued in conjunction with the original promissory note. This note is separate from the 8 % convertible debenture agreement that the Company has in place with Satco International, Ltd. (see note 7). As of September 30, 2022 accrued interest on the note totaled $ 35,638 . (6) NOTES PAYABLE, RELATED PARTY As of both September 30, 2022, and March 31, 2022, the Company had borrowed $ 3,001,808 , excluding accrued interest, from related parties. The interest associated with the Notes Payable, Related Party of $ 905,371 and $ 767,358 is recorded on the balance sheet as an Accrued Expense obligation at September 30, 2022 and March 31, 2021, respectively. Related Party Promissory Notes As of both September 30, 2022 and March 31, 2022, the Company owed $ 826,000 under the unsecured promissory notes from Mr. Dickman. The promissory notes bear interest at a rate of 8 % annually. The notes are due July 31, 2023 , or at the immediate time when alternative financing or other proceeds are received. During the six months ended September 30, 2022, the Company neither borrowed any additional funds under this agreement nor made any principal repayments. As of September 30, 2022, accrued interest on the notes totaled $ 265,727 . In the event the Company completes a successful equity raise all principal and interest on the notes are due in full at that time. As discussed in Note 4, a provision to the lending agreement provides the related party lender with common stock warrants upon the lenders extension of a maturity due date or upon the loaning of additional monies. No new warrants were issued during the six months ended September 30, 2022. The total number of warrants issued to the related party lender was 1,690,583 as of September 30 , 2022 (see Note 4 for further details on these warrants). On July 29, 2021, the Company entered into an unsecured promissory note agreement with Radiant Life, LLC. This agreement was in conjunction with the Company borrowing $ 50,000 of Notes Payable, Related Party on the date of the agreement, and is not part of the existing note payable and lines of credit agreement the Company has with Radiant Life, LLC that is outlined below in this Note 6. The $ 50,000 promissory note bears interest at a rate of 8 % annually and was due on July 29, 2022 . On August 3, 2022, the promissory note was amended to extend the due date from July 29, 2022 to July 29, 2023 , or at the immediate time when alternative financing or other proceeds are received. As of September 30, 2022, accrued interest on the note totaled $ 4,917 . 11 SUNDANCE STRATEGIES, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) September 30, 2022 Related Party Note Payable and Line of Credit Agreements As of both September 30, 2022 and March 31, 2022 , the Company owed $ 1,066,300 , exclusive of accrued interest, under the note payable and line of credit agreement with the Chairman of the Board of Directors and a stockholder. The note is due November 30, 2023 or at the immediate time when alternative financing or other proceeds are received. As of September 30, 2022 , the agreement allowed for borrowings of up to $ 4,600,000 . During the six months ended September 30, 2022, the Company neither borrowed any additional funds under this agreement nor made any principal repayments. The note payable and line of credit agreement incurs interest at 7.5 % per annum and are collateralized by the Company’s NIBS, if any. As of September 30, 2022 , accrued interest on this note totaled $ 262,276 . As discussed in Note 4, a provision to the lending agreement provides the related party lender with common stock warrants upon the lenders extension of a maturity due date or upon the loaning of additional monies. No new warrants were issued during the six months ended September 30, 2022. The total number of warrants issued to the related party lender was 2,380,150 as of September 30 , 2022 (see Note 4 for further details on these warrants). As of September 30, 2022 and March 31, 2021, the Company owed $ 1,059,508 in principle under the note payable and lines of credit agreement with Radiant Life, LLC. The agreement allows for borrowings of up to $ 2,130,000 . The principal and interest on the note are due November 30, 2023 or at the immediate time when alternative financing or other proceeds are received. The note payable and line of credit agreement incurs interest at 7.5 % per annum and is collateralized by the Company’s NIBS, if any. During the six months ended September 30, 2022 the Company neither borrowed nor repaid any principal under this agreement. As of September 30, 2022, accrued interest on this agreement totaled $ 372,450 . As discussed in Note 4, a provision to the lending agreement provides the related party lender with common stock warrants upon the lenders extension of a maturity due date or upon the loaning of additional monies. No new warrants were issued during the six months ended September 30, 2022. The total number of warrants issued to the related party lender was 1,679,508 as of September 30, 2022 (see Note 4 for further details on these warrants). (7) CONVERTIBLE DEBENTURE AGREEMENT The Company has entered into an 8% convertible debenture agreement with Satco International, Ltd., that allows for borrowings of up to $ 3,000,000 . The holder originally had the option to convert the outstanding principal and accrued interest to unregistered, restricted common stock of the Company on June 2, 2016. Per the agreement, the number of shares issuable at conversion shall be determined by the quotient obtained by dividing the outstanding principal and accrued and unpaid interest by 90% of the 90-day average closing price of the Company’s common stock from the date the notice of conversion is received; and the price at which the Debenture may be converted will be no lower than $ 1.00 per share. The original maturity date was June 2, 2016 , but was later extended, through a series of extensions, to July 5, 2022 . On August 9, 2022, the note was amended to extend the due date from July 5, 2022 to November 30, 2023 , or at the immediate time when alternative financing or other proceeds are received. This extension has no bearing on the warrants that were issued in conjunction with the original promissory note. As of September 30, 2022 and March 31, 2022, the Company owed $ 0 under the agreement, excluding accrued interest. The associated interest of $ 124,225 is recorded on the balance sheet as an Accrued Expense obligation at September 30, 2022 and March 31, 2022. (8) SUBSEQUENT EVENTS Subsequent to September 30, 2022, the following events transpired: On October 19, 2022, the unsecured promissory note with Satco International, Ltd. was amended to extend the due date from September 6, 2022 to January 6, 2023 , or at the immediate time when alternative financing or other proceeds are received. This extension has no bearing on the warrants that were issued in conjunction with the original promissory note. Between October 4, 2022 and November 8, 2022, the Company borrowed an additional $ 72,000 under the note payable and lines of credit agreement with the Chairman of the Board of Directors and a stockholder . As per the provision outlined in Note 4, and in conjunction with the extension of the due date of the agreement, the Company also agreed to provide the Chairman of the Board of Directors and a stockholder with warrants for 144,000 shares of common stock vested immediately upon issuance, with an exercise price of $ 1.05 per share and a 5-year exercise window from the date of the extension agreement. The warrants issued have no registration rights. On November 11, 2022, the unsecured promissory notes from Mr. Dickman were amended to extend the due date from October 31, 2022 to July 31, 2023 , or at the immediate time when alternative financing or other proceeds are received. As per the provision outlined in Note 4, and in conjunction with the extension of the due date of the agreement, the Company also agreed to provide Mr. Dickman with warrants for 399,749 shares of common stock vested immediately upon issuance, with an exercise price of $ 1.05 per share and a 5-year exercise window from the date of the extension agreement. The warrants issued have no registration rights. 12 Item 2. Management’s Discussions and Analysis of Financial Condition and Results of Operations. This discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and capital resources at and during the six months ended September 30, 2022 and 2021. For a complete understanding, this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Financial Statements and Notes to the Financial Statements contained in this quarterly report on Form 10-Q and our annual report on Form 10-K for the year ended March 31, 2022. Forward-looking Statements This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are based on management’s beliefs and assumptions and on information currently available to management. For this purpose any statement contained in this report that is not a statement of historical fact may be deemed to be forward-looking, including, but not limited to, statements relating to our future actions, intentions, plans, strategies, objectives, results of operations, cash flows and the adequacy of or need to seek additional capital resources and liquidity. Without limiting the foregoing, words such as “ may ”, “ should ”, “ expect ”, “ project ”, “ plan ”, “ anticipate ”, “ believe ”, “ estimate ”, “ intend ”, “ budget ”, “ forecast ”, “ predict ”, “ potential ”, “ continue ”, “ should ”, “ could ”, “ will ” or comparable terminology or the negative of such terms are intended to identify forward-looking statements, however, the absence of these words does not necessarily mean that a statement is not forward-looking. These statements by their nature involve known and unknown risks and uncertainties and other factors that may cause actual results and outcomes to differ materially depending on a variety of factors, many of which are not within our control. Such factors include, but are not limited to, economic conditions generally and in the industry in which we and our customers participate; competition within our industry; legislative requirements or changes which could render our products or services less competitive or obsolete; our failure to successfully develop new products and/or services or to anticipate current or prospective customers’ needs; price increases; employee limitations; or delays, reductions, or cancellations of contracts we have previously entered into; sufficiency of working capital, capital resources and liquidity and other factors detailed herein and in our other filings with the United States Securities and Exchange Commission (the “SEC” or “Commission”). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Forward-looking statements are predictions and not guarantees of future performance or events. Forward-looking statements are based on current industry, financial and economic information which we have assessed but which by its nature is dynamic and subject to rapid and possibly abrupt changes. Our actual results could differ materially from those stated or implied by such forward-looking statements due to risks and uncertainties associated with our business. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements and we hereby qualify all our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of their dates and should not be unduly relied upon. We undertake no obligation to amend this report or revise publicly these forward-looking statements (other than pursuant to reporting obligations imposed on registrants pursuant to the Exchange Act) to reflect subsequent events or circumstances, whether as the result of new information, future events or otherwise. The following discussion should be read in conjunction with our financial statements and the related notes contained elsewhere in this report and in our other filings with the Commission. Overview Our historical business model has focused on purchasing or acquiring life insurance policies and residual interests in or financial products tied to life insurance policies, including notes, drafts, acceptances, open accounts receivable and other obligations representing part or all of the sales price of insurance, life settlements and related insurance contracts being traded in the secondary marketplace, often referred to as the “life settlements market.” 13 We currently do not hold life settlement or life insurance policies but, rather, previously held a contractual right to receive the net insurance benefits, or “NIBs”, from a portfolio of life insurance policies held by a third party (“the Owners” or “the Holders”). These NIBs represented an indirect, residual ownership interest in a portfolio of individual life insurance policies, and they allowed us to receive a portion of the settlement proceeds from such policies, after expenses related to the acquisition, financing, insuring and servicing of the policies underlying our NIBs have been paid. NIBs are generally sold by an entity that holds the underlying life settlement or life insurance policies, either directly or indirectly through a subsidiary, such an entity being referred to herein as a “Holder.” A Holder, either directly or through a wholly owned subsidiary, purchases life insurance policies either from the insured or on the secondary market and aggregates them into a portfolio of policies. At the time of purchase, the Holder also (i) contracts with a service provider to manage the servicing of the policies until maturity, (ii) consider purchasing mortality re-insurance (“MRI”) coverage under which payments will be made to the Holder in the event the insurance policies do not mature according to actuarial life expectancies, and (iii) arranges financing to cover the initial purchase of the insurance policies, the servicing of the life insurance policies until maturity and the payment of the MRI premiums. The financing obtained by the Holder for a portfolio of life settlement or life insurance policies is secured by the insurance policies for which the financing was obtained. After a Holder purchases policies, aggregates them into a portfolio and arranges for the servicing, MRI coverage and financing, the Holder contracts to sell NIBs related to the policies, which gives the holder of the NIBs the right to receive the proceeds from the settlement of the insurance policies after all of the expenses related to such policies have been paid. When an insurance policy underlying our NIBs comes to maturity, the insurance proceeds are first used to pay expenses associated with such policy. Once all of the expenses have been paid, the Holder will retain a small percentage of the proceeds and then will pay the remaining insurance proceeds to us. During the latter part of the fiscal year ended March 31, 2021, we began developing an additional business offering, providing professional services to specialty structured finance groups, bond issuers and life settlement aggregators. We have assembled an experienced team from the life settlement marketplace, as well as from other areas such as financial services and public financial markets. As a professional services provider, we apply industry best practices to advise on the selection of specific portfolios of life insurance policies that are tailored to meet the needs of its clients. Our clients may include bond issuers, bond investors, or other structured finance product issuers. We develop strategies and methodologies which include the acquisition of life insurance portfolios, then use common structured finance techniques and proprietary analytics to structure bonds for issuances, including principal protected bonds. Our goal is to deliver long-term value and profitability to shareholders by growing our professional services business and asset base, resulting in the ability to pay dividends to its shareholders. During the latter part of the year ended March 31, 2021, we began working closely with bond placement agents and aggregators to establish various aspects of a proprietary, investment grade bond offering. In this arrangement, we participate as the sole originator in the role of structuring and advising on the structure of the proprietary bond instrument. Included in the role of structuring financial assets, we use proprietary analytics to establish the makeup of the rated instrument, including but not limited to, life settlement assets (life insurance policies) and managed cash, and implements a process of selective assembly of the underlying assets and cash management that will meet the policy requirements and analytics. We provide current and ongoing resources for all analytics, as well as advisement support for the investment and non-investment grade ratings for the managed asset pool and the managed cash accounts. In our advisory role, we are reimbursed for all expenses associated with the structuring and preparation of any bond offering, will receive an advisory payment upon the closing of any bond offering, and then will hold residual rights on the balance of assets once the bond is retired. On January 1, 2022, we entered into a marketing and consulting agreement with Tradability, LLC (“Consultant”) that requires us to make an initial $100,000 payment and up to an additional $400,000 in the future (which will be financed by the Consultant via a promissory note). The $400,000 obligation is contingent upon the Consultant and us successfully reaching certain milestones. Further, the agreement requires us to issue between 1,000,000 and 10,000,000 stock options (which are exercisable into our common stock at prices between $1.00 to $2.50 per share) contingent upon the Consultant and us successfully reaching certain milestones. The milestones primarily relate to the Consultant finalizing the tokenization of 500 million non-fungible tokens (“NFTs”) and the successful placement of NFTs with proceeds of between $100 million and $500 million. The proceeds will be used to purchase Life Settlements for which we will be an advisor. As of June 30, 2022 none of the milestones related to the potential issuance of equity have been met. 14 Plan of Operations Life Settlements is not a market sector without competition and, at present, we are a minor competitor. We will need substantial additional funds to effectively compete in this industry and no assurance can be given that we will be able to adequately fund our current and intended operations through debt or equity financing. The Company has no current source of operating revenues. When we hold NIBs we may be required to expend funds on premiums, interest and servicing costs to protect our interest in NIBs, though we have no legal responsibility nor adequate funds for these payments. In the event that neither party fulfils the financial obligations pertaining to the premiums, interest and servicing costs, we would be required to evaluate our investment in NIBs for possible adverse impairment. When we hold NIBs, we use an estimation methodology to project cash flows and returns as presented. The estimation model requires many assumptions, including, but not limited to the following: (i) an assumption that the distinct number of lives in our portfolio would exhibit similar experience to a statistically diverse portfolio from which mortality tables have been created; (ii) an assumption that the life expectancies (the “LE” or “LEs”) provided by LE providers represent the actuarial mean of the life expectancies of the insureds in our portfolio, (iii) the weighted average of the LEs provided by the LE providers represents an appropriate method for adjusting for discrepancies in the LEs; (iv) life expectancy tables and projections are accurate; (v) the minimum premiums calculated based on the in-force illustrations provided by life insurance carriers are accurate and will not change over the course of the lifetime of our portfolio; and (vi) the Holders’ Lender fees, MRI fees, and insurance, servicing and custodial fees will not change materially over time. While this method of modeling cash flows is helpful in providing a theoretical expectation of potential returns that might be produced from our NIBs portfolio, actual cash flows and returns inevitably will be different (possibly materially) due to the fact that predicting the exact date of death of any individual is virtually impossible. The provision of a theoretical cash flow model is by no means any guarantee of any results. The actual performance of these NIB interests (as well as our future expectations as to what such performance might be) may differ substantially from our expectations, especially if any of the assumptions change or differ from our initial assumptions. Results of Operations Three-Months Ended September 30, 2022, Compared with Three-Months Ended September 30, 2021 Income from Investments Due to the Company not holding NIBs, no interest income was recorded for the three months ended September 30, 2022 or 2021. General & Administrative Expenses General and administrative expenses totaled $161,534 and $172,144 during the three months ended September 30, 2022, and 2021, respectively. A significant portion of these expenses were professional fees and payroll costs. The decrease in expenses was primarily due to a decrease in professional fees. Other Income and Expenses For the three months ended September 30, 2022 and 2021, other expenses related to pursuing potential financing alternatives were $13,500 and $10,000, respectively. During the three months ended September 30, 2022, and 2021, interest expense accrued in the amount of $75,907 and $68,352, respectively. The increased interest expense was due to higher principal balances on our notes payable. 15 Income Taxes During the three months ended September 30, 2022, the Company recorded a net loss before income taxes of $250,941, and had no income tax expense or benefit as a result of a full valuation allowance on the net deferred tax asset. Six-Months Ended September 30, 2022, Compared with Six-Months Ended September 30, 2021 Income from Investments Due to the Company not holding NIBs, no interest income was recorded for the six months ended September 30, 2022 or 2021. General & Administrative Expenses General and administrative expenses totaled $375,491 and $415,605 during the six months ended September 30, 2022, and 2021, respectively. A significant portion of these expenses were professional fees and payroll costs. The decrease in expenses was primarily due to a decrease in professional fees. Other Income and Expenses During the six months ended September 30, 2021, we negotiated a settlement to reduce our outstanding accounts payable to one of our vendors by $285,192. The gain was recorded as a gain on settlement of liabilities. For the six months ended September 30, 2022 and 2021, other expenses related to pursuing potential financing alternatives were $27,000 and $87,561, respectively. During the six months ended September 30, 2022, and 2021, interest expense accrued in the amount of $150,046 and $133,737, respectively. The increased interest expense was due slightly higher principal balances on our notes payable. Income Taxes During the six months ended September 30, 2022, the Company recorded a net loss before income taxes of $552,537, and had no income tax expense or benefit as a result of a full valuation allowance on the net deferred tax asset. Liquidity and Capital Resources Since our inception our operations have been primarily financed through sales of equity instruments, debt financing, lines of credit and notes payable from related and unrelated parties and the issuance of convertible debentures. As of September 30, 2022, we had $498 of cash, compared to $267,966 as of March 31, 2022. As of September 30, 2022, the Company had access to draw an additional $4,604,192 on the notes payable, related party and $3,000,000 on the Convertible Debenture Agreement. Our monthly expenses are anticipated to be approximately $70,000, which includes salaries of our employees, policy servicing expenses, consulting agreements and contract labor, general and administrative expenses, and estimated legal and accounting expenses. Outstanding Accounts Payable as of September 30, 2022 totaled $665,270, short term notes payable totaled $300,000, short term notes payable to related parties totaled $876,000, and other accrued short term liabilities totaled $455,039. We believe that our availability under our existing lines of credit with related parties, our existing capital resources, together with the issuance of additional notes payable and convertible debentures will be sufficient to fund our operating working capital requirements for at least the next 12 months, or through November 2023. 16 Debt At September 30, 2022, we owed $4,367,042, including accrued interest, for debt obligations. We owed $3,001,808 in principal pursuant to notes payable and lines-of-credits from related parties, $300,000 in other notes payable, and had fully paid off the principal owing on the 8% Convertible Debenture. As of September 30, 2022, one note payable and line-of-credit had a principal balance of $1,109,508 and is due on November 30, 2023, or when the Company completes a successful equity raise, at which time principal and interest is due in full. The second note payable and line-of-credit had a principal balance of $1,066,300, and the line of credit is currently extended through November 30, 2023. At September 30, 2022, unsecured promissory notes with related parties had principal balances totaling $826,000, and are due July 31, 2023. The convertible debenture agreement, which has no principal balance due as of September 30, 2022 is open through November 30, 2023. As of November 14, 2022, there was $4,532,192 available under the lines-of-credit we currently have with related parties and $3,000,000 available under the 8% convertible debenture agreement. Critical Accounting Policies and Estimates See Consolidated Financial Statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2022, which was filed with the SEC on June 29, 2022. Off-Balance Sheet Arrangements We have no off-balance sheet arrangements. Item 3. Quantitative and Qualitative Disclosure about Market Risk Not Applicable. Item 4. Controls and Procedures Limitation on the Effectiveness of Controls The Company maintains disclosure controls and procedures that are designed to provide reasonable assurance that information, which is required to be disclosed timely, is accumulated and communicated to management in a timely fashion. In designing and evaluating such controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management is necessarily required to use judgment in evaluating controls and procedures. Evaluation of Controls and Procedures Our management, with the participation of our principal executive and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to the issuer’s management, including its Principal Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officer has concluded that our disclosure controls and procedures as of the end of the period covered by the Quarterly Report were not effective due to the lack of design and operating effectiveness of our control environment and risk assessment, control activities and monitoring activities relating to complex accounting matters relating to the valuation of equity-based compensation instruments as disclosed in Item 9A of our 10K filed on June 29, 2022. Our principal executive and principal financial officer is in the process of performing a review of our processes and controls over complex accounting matters relating to the valuation of equity-based compensation instruments. Changes in Internal Control There were no changes in our internal control over financial reporting that occurred during the second quarter of 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 17 PART II - OTHER INFORMATION Item 1. Legal Proceedings To the best of our knowledge, there are no legal proceedings pending or threatened against us; and there are no actions pending or threatened against any of our directors or officers that are adverse to us. Item 1A. Risk Factors In addition to the other information set forth in this quarterly report on Form10-Q, you should carefully consider the risks discussed in our Annual Report on Form 10-K for the year ended March 31, 2022, which risks could materially affect our business, financial condition or future results. There were no material changes during the quarter ended September 30, 2022 to the risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022. These risks are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Purchases of Equity Securities by the Issuer There were no repurchases of equity during the quarter ended September 30, 2022. Item 3. Defaults upon Senior Securities. None; not applicable. Item 4. Mine Safety Disclosures. None; not applicable. Item 5. Other Information. None; not applicable. 18 Item 6. Exhibits Exhibits. The following exhibits are included as part of this report: Exhibit 10.37* Private Placement Memorandum, effective November 5, 2022 Exhibit 10.38* Agreement between Sundance Strategies, Inc. and Tradability, LLC, dated January 1, 2022 Exhibit 31.1 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act provided by Randall F. Pearson, President and Director. Exhibit 31.2 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act provided by Randall F. Pearson, Principal Financial Officer. Exhibit 32 Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 provided by Randall F. Pearson, President and Principal Financial Officer. Exhibit 101.INS XBRL Instance Document Exhibit 101.SCH Inline XBRL Taxonomy Extension Schema Document Exhibit 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Exhibit 101.DEF Inline XBRL Taxonomy Definition Linkbase Document Exhibit 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document Exhibit 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Exhibit 104 Cover Page Interactive Data File * Previously filed as an Exhibit to the registrant’s Annual Report on Form 10-K for the year ended March 31, 2022, filed with the Securities and Exchange Commission on June 29, 2022, and incorporated herein by reference. +Filed herewith. 19 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SUNDANCE STRATEGIES, INC. Date: November 14, 2022 By: /s/ Randall F. Pearson Randall F. Pearson President and Principal Financial Officer 20